In my view, the next big announcement shall be a big pharma partner for COVID-19. The last 4C put the discussions ongoing for at least a month. During the last conf call, the CFO refused to get drawn into a discussion or answer the analyst question on funds allocated for manufacturing in next quarters. Maybe the last fresh equity funds raise put the company in a better negotiation position, but won’t actually be needed for manufacturing if there is a big pharmaceutical partnership....
Here is an excerpt from MESOBLAST’s last 4C: “Mesoblast is in active discussions with US and other government authorities as well as potential pharmaceutical partners with respect to its plans for ramp-up of commercial manufacturing for remestemcel-L in COVID-19 ARDS.”
http://investorsmedia.mesoblast.com/static-files/04851ade-aca5-492c-9784-45ae8c772f04
Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease, page-144
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.015(1.40%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $11.51M | 10.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17804 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 230637 | 5 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.015 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 1937390 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| MSB (ASX) Chart |